GENinCode (LON:GENI) Trading Down 7.7% – Here’s Why
by Kim Johansen · The Markets DailyGENinCode Plc (LON:GENI – Get Free Report)’s share price was down 7.7% during mid-day trading on Friday . The stock traded as low as GBX 0.85 and last traded at GBX 0.88. Approximately 4,606,875 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 5,226,285 shares. The stock had previously closed at GBX 0.95.
GENinCode Stock Down 7.7%
The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74. The stock has a market cap of £6.60 million, a PE ratio of -0.42 and a beta of 0.59. The business has a 50 day moving average of GBX 0.87 and a 200-day moving average of GBX 1.01.
GENinCode (LON:GENI – Get Free Report) last released its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. The business had revenue of GBX 308 million during the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. Equities research analysts predict that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.
GENinCode Company Profile
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.